Raymond James Financial
FOLD

Raymond James Financial’s Amicus Therapeutics FOLD Stock Holding History

Raymond James Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Buy
+19,565
New +$280K ﹤0.01% 4686
2025
Q3 		– Sell
-8,309
Closed -$47.6K – 5599
2025
Q2 		$47.6K Sell
8,309
-2,208
-21% -$14.3K ﹤0.01% 5199
2025
Q1 		$85.8K Sell
10,517
-3,466
-25% -$32.1K ﹤0.01% 4571
2024
Q4 		$132K Buy
+13,983
New +$145K ﹤0.01% 4487

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Raymond James Financial's FOLD Position: Q1 2026 in Review

Raymond James Financial opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 19,565 shares worth $283K. The stake represents ﹤0.01% of the portfolio and ranks #4686 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in FOLD as recently as Q2 2025.

Raymond James Financial first reported a position in FOLD in Q4 2024 and has held it in 4 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Raymond James Financial held 19,565 shares of Amicus Therapeutics worth $283K as of Q1 2026.
  • Amicus Therapeutics was a new Raymond James Financial position in Q1 2026.
  • Amicus Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4686 holding.
  • Raymond James Financial first reported a position in Amicus Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.